Abeona Therapeutics (ABEO) Stifel Virtual Cell Therapy Forum summary

Company overview and lead program

• Transitioning from R&D to commercial stage with a clear path to profitability.

• Lead program pz-cel targets recessive dystrophic epidermolysis bullosa (RDEB), a severe connective tissue disorder.

• Pz-cel is an autologous engineered cell therapy designed to restore collagen VII and promote durable wound healing.

• Clinical studies show sustained wound healing and pain reduction for years after a single treatment.

• Additional pipeline includes preclinical AAV-based gene therapies for ophthalmology and partnered programs.

Clinical data and differentiation

• Phase I/IIa and pivotal Phase III studies demonstrate significant wound healing in chronic, large wounds unresponsive for years.

• Treated wounds showed no spontaneous healing in control arms, highlighting the therapy's impact.

• Efficacy observed across multiple anatomical locations, with potential label expansion beyond toughest wounds.

• No squamous cell carcinomas observed in treated sites, though data is not yet statistically robust.

• Registry data will be collected post-launch to further monitor long-term outcomes.

Safety and regulatory status

• Gamma-retroviral vector used for gene integration; no replication-competent retrovirus detected in over 120 monitored samples.

• Literature and clinical experience suggest extremely low risk of insertional oncogenesis.

• Risk-benefit profile considered favorable given the high baseline risk of squamous cell carcinoma in RDEB.

• No efficacy or safety concerns raised in the recent Complete Response Letter (CRL); focus is on manufacturing and assay validation.